Skip to content

US · DXCM · MEDICAL - DEVICES

DexCom, Inc. (DXCM) intrinsic value and stock valuation

$79.32as of 2026-11-21 · Mkt cap 31.19B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

DexCom, Inc. DCF and intrinsic value

InvestorsCraft values DXCM with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from DXCM’s statements →

DexCom, Inc. Graham Number

Graham Number: $18.42d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices San Diego, CA 92121 dexcom.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$4.66B+19.3% 5y CAGRd
20112025
Net income
$836.3M+11.1% 5y CAGRd
20112025
Free cash flow
$1.08B+31.2% 5y CAGRd
20112025
Total equity
$2.75B+8.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$4.66B$4.03B$3.62B$2.91B$2.45B
Operating income$911.8M$600M$597.7M$391.2M$265.8M
Net income$836.3M$576.2M$541.5M$341.2M$216.9M
EPSd$2.06M$1.4M$1.27M$798.1K$505.8K
Operating cash flow$1.44B$989.5M$748.5M$669.5M$442.5M
Capital expenditure-$-363.5M-$-358.8M-$-236.6M-$-364.8M-$-389.2M
Free cash flow$1.08B$630.7M$511.9M$304.7M$53.3M
Total assets$6.34B$6.48B$6.26B$5.39B$4.93B
Total debt$1.39B$2.59B$2.59B$2.15B$2.16B
Net debt$472M$1.98B$2.03B$1.5B$1.11B
Total equity$2.75B$2.1B$2.07B$2.13B$2.04B
Cash and short-term investments$2B$2.58B$2.72B$2.46B$2.73B
Income statement
20252024202320222021
Revenue$4.66B$4.03B$3.62B$2.91B$2.45B
Cost of revenue$1.86B$1.59B$1.33B$1.03B$768M
Gross profit$2.8B$2.44B$2.29B$1.88B$1.68B
Research and development expenses$599.1M$552.4M$505.8M$484.2M$604.2M
Selling, general and administrative expenses$1.29B$1.29B$1.19B$1.01B$810.5M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$1.89B$1.84B$1.69B$1.49B$1.41B
Cost and expenses$3.75B$3.43B$3.02B$2.52B$2.18B
Interest income$112.7M$134.2M$135M$23.8M$1.7M
Interest expense$18.3M$19M$20.3M$18.6M$18.8M
Depreciation and amortization$251.8M$217.7M$186M$155.9M$101.9M
Ebitda$1.36B$945.7M$916.7M$565.3M$377.5M
Operating income$911.8M$600M$597.7M$391.2M$265.8M
Total other income/expenses, net$176.6M$109M$112.7M-$-400K-$-9M
Income before tax$1.09B$709M$710.4M$390.8M$256.8M
Income tax expense$252.1M$132.8M$168.9M$49.6M$39.9M
Net income$836.3M$576.2M$541.5M$341.2M$216.9M
Weighted average shares outstanding$390.2M$404.6M$386M$389.4M$386.9M
Weighted average diluted shares outstanding$405.5M$412.7M$425.5M$427.5M$428.8M
Balance sheet
20252024202320222021
Cash and short-term investments$2B$2.58B$2.72B$2.46B$2.73B
Net receivables$1.29B$1.03B$987.5M$752.2M$516.6M
Inventory$629.1M$542.6M$559.6M$306.7M$357.3M
Total current assets$4.03B$4.3B$4.43B$3.67B$3.68B
Property, plant and equipment, net$1.64B$1.4B$1.18B$1.14B$889.9M
Goodwill and intangible assets$95M$126.2M$159.7M$199M$58M
Long-term investments$218M$119.3M$38.5M$19M$0.00
Total non-current assets$2.31B$2.18B$1.84B$1.72B$1.25B
Total assets$6.34B$6.48B$6.26B$5.39B$4.93B
Accounts payable$344.3M$345.3M$276.4M$237.9M$189.4M
Short-term debt$21.6M$1.23B$21.1M$793.1M$20.5M
Deferred revenue$7.7M$8M$18.4M$10.1M$2.1M
Total current liabilities$2.14B$2.93B$1.56B$1.84B$720.8M
Long-term debt$1.37B$1.36B$2.57B$1.35B$2.14B
Deferred revenue, non-current$0.00$9.5M$7.4M$19M$16.1M
Total non-current liabilities$1.45B$1.45B$2.64B$1.42B$2.17B
Capital lease obligations$148.8M$146M$159.8M$174.7M$176.1M
Total liabilities$3.59B$4.38B$4.2B$3.26B$2.89B
Common stock$400K$400K$400K$400K$400K
Retained earnings$2.43B$1.6B$1.02B$479.9M$138.7M
Accumulated other comprehensive income (loss)$115M-$-8M-$-16.7M-$-11.6M$500K
Total equity$2.75B$2.1B$2.07B$2.13B$2.04B
Total investments$1.3B$2.09B$2.2B$1.83B$1.68B
Total debt$1.39B$2.59B$2.59B$2.15B$2.16B
Net debt$472M$1.98B$2.03B$1.5B$1.11B
Cash flow statement
20252024202320222021
Net income$836.3M$576.2M$541.5M$341.2M$154.7M
Depreciation and amortization$251.8M$217.7M$186M$155.9M$102M
Stock-based compensation$159.6M$170.4M$150.8M$126.5M$113.4M
Change in working capital$103.4M$108.8M$3.2M$27.7M-$-132M
Accounts receivable-$-201.9M-$-35M-$-260.1M-$-199.9M-$-75.5M
Inventory-$-63.7M$12.4M-$-252.6M$49.3M-$-112.2M
Accounts payable$347M$211.7M$466.5M$295.1M$58M
Net cash provided by operating activities$1.44B$989.5M$748.5M$669.5M$442.5M
Investments in property, plant and equipment-$-363.5M-$-358.8M-$-236.6M-$-364.8M-$-389.2M
Acquisitions, net$0.00$0.00$0.00-$-3.9M-$-30.2M
Net cash used for investing activities$536M-$-207.5M-$-507.2M-$-521.5M-$-216.1M
Common stock issued$28.1M$28.2M$26.6M$22.5M$20.3M
Common stock repurchased-$-500M-$-750M-$-688.7M-$-557.7M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-1.69B-$-734.8M-$-318.6M-$-552.5M$10.4M
Net change in cash$311.8M$39.8M-$-75.8M-$-410.3M$235.4M
Cash at end of period$919.1M$607.3M$567.5M$643.3M$1.05B
Operating cash flow$1.44B$989.5M$748.5M$669.5M$442.5M
Capital expenditure-$-363.5M-$-358.8M-$-236.6M-$-364.8M-$-389.2M
Free cash flow$1.08B$630.7M$511.9M$304.7M$53.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About DexCom, Inc.

        DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

        CEO
        Jacob Steven Leach
        Employees
        11.1K
        Beta
        1.45

        Explore

        Frequently asked questions

        What is the intrinsic value of DexCom, Inc. (DXCM)?

        DexCom, Inc. (DXCM) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is DXCM undervalued?

        DXCM trades at a price of $79.32 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.